ArticleiScience2026
A comprehensive toolkit for analyzing cell-free DNA genomic sequencing data in liquid biopsy.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The future of fungal diagnostics: What's next in laboratory testing for invasive fungal infection?Medical mycology · 2026Review
- Multifeature sequencing-based liquid biopsy for cancer diagnosis and monitoring.Genome medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy via plasma cell-free DNA (cfDNA) is transforming precision medicine by enabling non-invasive insights into the genomic and epigenomic landscapes of disease, especially cancer. However, the increasing diversity of cfDNA-derived features and machine learning applications has outpaced the availability of unified, versatile computational tools. To bridge this gap, we present cfDNAanalyzer-a user-friendly toolkit for streamlined cfDNA analysis, integrating feature extraction, selection, and machine learning model construction. Designed mainly for researchers and clinicians with limited bioinformatics expertise, it supports multimodal integration, interpretable output, and automated preprocessing. Benchmarking against existing toolkits demonstrated that cfDNAanalyzer provides broader feature coverage, efficient runtime, and comparable or improved predictive accuracy across shared feature types. We demonstrate its utility using real-world cfDNA datasets, uncovering its capability to discover biologically meaningful signals and improve diagnostic performance through feature integration. By standardizing and accelerating cfDNA analysis, cfDNAanalyzer enables reproducible biomarker discovery and advances translational liquid biopsy research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.